CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project focuses on enhancing the effectiveness of Ethionamide, a key drug for treating multidrug-resistant tuberculosis, by combining it with two proprietary compounds. The goal is to improve treatment outcomes and reduce side effects, making it possible to treat resistant strains of the disease more effectively.
Tuberculosis (TB) is the world’s leading infectious disease.
It killed 1.7 million people in 2016 and 10.4 million people developed active TB in the same year.
In 2016, 480’000 of TB cases were multidrug-resistant (MDR-TB) and 9% percent of those cases are extensively drug-resistant (XDR), with mortality rates as high as 70%.
Ethionamide (ETH) is a vital part of the WHO essential medicines list of 2nd-line TB therapy for MDR-TB, however, ETH suffers from significant levels of resistance and side…
BIOVERSYS AG
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
France, Lille
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
Spain, Tres Cantos
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
